In This Article
- Citizens, Inc. (CIA)
⚠ Volatility Notice: This article contains micro-cap and/or small-cap stocks (under $1B market cap). These companies tend to have lower trading volume and can experience significantly higher price volatility than large-cap stocks. Please exercise additional caution and conduct thorough due diligence before investing.
Citizens, Inc. (NYSE: CIA)
$3.52
Overall Grade1.9 / 10
Citizens, Inc. (NYSE: CIA) is an insurance holding company that provides life insurance and related protection products to individuals and small businesses...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E27.3
P/B1.2
P/S1.1
P/FCF19.4
FCF Yield+5.1%
Growth & Outlook
Rev Growth (YoY)+3.7%
EPS Growth (YoY)-8.7%
Revenue 5yr+0.9%
EPS 5yr-
FCF 5yr-
Fundamentals
Market Cap$177M
Dividend Yield-
Operating Margin+5.6%
ROE+5.0%
Interest Coverage-
Competitive Edge
- The international segment selling USD-denominated whole life to Latin American and Pacific Rim clients fills a genuine niche. Wealthy non-US individuals wanting dollar-based protection face limited options, creating natural switching costs.
- Zero goodwill on the balance sheet means no acquisition-driven impairment risk. The asset base is real, consisting of investment securities and policy reserves rather than purchased intangibles.
- Whole life and endowment products generate long-duration, predictable premium streams. Policyholder behavior in international markets tends toward lower lapse rates due to the dollar-denominated savings component.
- Operating in a heavily regulated industry with high barriers to entry. Licensing requirements across multiple Latin American jurisdictions create a distribution moat that new entrants cannot easily replicate.
By the Numbers
- Trading at 0.82x book value with tangible BV/share of $4.39 vs. $3.78 price, meaning you're buying the insurance book at a discount to liquidation value. For an insurer with no goodwill, this is meaningful.
- Net cash position of $17M on a $193M market cap (8.8% of market cap) eliminates refinancing risk entirely and provides optionality for capital deployment or reserve strengthening.
- FCF-to-net-income conversion of 1.29x signals high earnings quality. Cash generation exceeds reported profits, which is uncommon for life insurers and suggests conservative reserve accounting.
- Forward P/E of 12.7x vs. trailing 18.2x implies consensus expects ~43% earnings growth. PEG of 0.3 suggests the market is dramatically underpricing whatever growth trajectory the single covering analyst sees.
- SBC/revenue at just 0.78% is negligible dilution. Share count grew only 0.37% last year, confirming management isn't quietly eroding per-share economics through compensation.
Risk Factors
- EPS has compounded at negative 24% over 3 years and negative 32% over 5 years. The trailing P/E of 18x on a shrinking earnings base means you're paying more for less. Revenue flatlined while profits collapsed.
- EV/EBITDA of 50.9x is extreme for a life insurer, suggesting operating earnings power is very thin relative to enterprise value. This dwarfs the seemingly cheap P/B and P/S ratios.
- ROE of 4.9% is well below any reasonable cost of equity for a micro-cap insurer. At this return level, the company is destroying economic value even if accounting profits are positive.
- Revenue growth has been essentially zero for a decade (0.38% 10Y CAGR). With only one analyst covering the stock, there's minimal institutional scrutiny and price discovery is poor.
- Non-interest income declined 78% YoY, a severe drop that suggests investment portfolio losses or realized gains that won't repeat. This volatility in a key insurance income stream is a red flag.
